Innovassynth Technologies (India) Ltd
Incorporated in 2008, Innovassynth Technologies Ltd is a Contract Research, Development and Manufacturing Organization (CRDMO) specializing in pharmaceutical intermediates, oligonucleotide building blocks and specialty chemicals.
- Market Cap ₹ 626 Cr.
- Current Price ₹ 67.4
- High / Low ₹ 126 / 45.0
- Stock P/E
- Book Value ₹ 8.81
- Dividend Yield 0.00 %
- ROCE -9.18 %
- ROE -11.1 %
- Face Value ₹ 10.0
Pros
Cons
- Stock is trading at 7.65 times its book value
- Company has low interest coverage ratio.
- Company has a low return on equity of -6.02% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Commodities Chemicals Chemicals & Petrochemicals Commodity Chemicals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
|---|---|---|---|---|---|---|
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| 0.28 | 0.37 | 1.30 | 0.50 | 3.96 | 11.72 | |
| Operating Profit | -0.28 | -0.37 | -1.30 | -0.50 | -3.96 | -11.72 |
| OPM % | ||||||
| 0.00 | 1.86 | 0.02 | 0.00 | -0.33 | 7.40 | |
| Interest | 0.24 | 0.27 | 0.30 | 0.34 | 0.40 | 0.45 |
| Depreciation | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Profit before tax | -0.52 | 1.22 | -1.58 | -0.84 | -4.69 | -4.77 |
| Tax % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | |
| -0.52 | 1.22 | -1.58 | -0.84 | -4.69 | -4.77 | |
| EPS in Rs | -0.17 | 0.41 | -0.53 | -0.28 | -1.36 | -1.38 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | % |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | 26% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 24% |
| 5 Years: | 54% |
| 3 Years: | 43% |
| 1 Year: | -23% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | -6% |
| Last Year: | -11% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 | |
|---|---|---|---|---|---|
| Equity Capital | 24.28 | 24.28 | 24.28 | 27.98 | 27.98 |
| Reserves | 12.68 | 12.64 | 11.79 | 14.26 | 2.32 |
| 2.85 | 3.24 | 3.59 | 4.40 | 4.86 | |
| 0.94 | 1.22 | 1.56 | 1.96 | 2.20 | |
| Total Liabilities | 40.75 | 41.38 | 41.22 | 48.60 | 37.36 |
| 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| CWIP | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 40.74 | 41.35 | 41.21 | 48.53 | 37.28 |
| 0.01 | 0.03 | 0.01 | 0.07 | 0.08 | |
| Total Assets | 40.75 | 41.38 | 41.22 | 48.60 | 37.36 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| -0.32 | -0.34 | -0.33 | -0.73 | ||
| 0.00 | 0.00 | 0.00 | 0.00 | ||
| 0.32 | 0.36 | 0.32 | 0.77 | ||
| Net Cash Flow | 0.00 | 0.02 | -0.01 | 0.04 | |
| Free Cash Flow | -0.32 | -0.34 | -0.33 | -0.73 | |
| CFO/OP | 86% | 26% | 66% | 18% |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
| Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|
| Debtor Days | |||||
| Inventory Days | |||||
| Days Payable | |||||
| Cash Conversion Cycle | |||||
| Working Capital Days | |||||
| ROCE % | -3.20% | -1.25% | -9.18% |
Insights
In beta| Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|---|---|---|
| Turnover (Revenue) Rs. Crore ・Standalone data |
|
||||||
| Capital Structure (Gearing Ratio) times ・Standalone data |
|||||||
| Customer Concentration (Top Customer Revenue Share) % ・Standalone data |
|||||||
Extracted by Screener AI
Documents
Announcements
-
Board Meeting Intimation for Consider And Approve Matters Relating To The Rights Issue Of The Company By The Rights Issue Committee.
2d - Rights Issue Committee meets on May 19, 2026 to consider allotment after issue closes May 18.
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
5 May - Newspaper publication of the pre-issue advertisement of the rights issue.
-
Completion Of Dispatch Of Letter Of Offer Along With The Issue Material For Rights Issue.
4 May - Letter of Offer submitted for ₹69.64 crore rights issue of 1.74 crore shares at ₹40 each.
-
Revision In Outcome Of Rights Issue Committee Meeting Dated Thursday, April 23, 2026.
30 Apr - Rectified rights issue outcome: pre-issue shares 7.54 crore, post-issue 9.29 crore; no other changes.
-
Submission Of Letter Of Offer For Rights Issue Of Fully Paid-Up Equity Shares Of Innovassynth Technologies (India) Limited.
24 Apr - Letter of offer filed for 1.74 crore rights shares at ₹40, issue opens May 8, 2026.
Annual reports
-
Financial Year 2025
from bse
-
Financial Year 2024
from bse
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2011
from bse
Concalls
-
Feb 2026TranscriptAI SummaryPPT
Business Overview:[1]
Innovassynth Technologies is a chemistry-focused CRDMO company engaged in research, development, and manufacturing across three key verticals — pharmaceutical intermediates, oligonucleotide building blocks, and specialty chemicals. It provides end-to-end services including custom synthesis, process development, scale-up, and commercial manufacturing for global life sciences and advanced materials customers. The company's oligonucleotide vertical focuses on nucleosides and amidites used in DNA/RNA therapeutics, while the specialty chemicals vertical serves applications in polyolefins, organometallic catalysts, and semiconductor materials. ITL uses chemistry capabilities, process innovation, and manufacturing expertise, to position itself as a long-term partner for global pharmaceutical and specialty chemical companies.